Pancreatic tumors reprogram immune cells that normally shut down tumor-killing cells, according to a team at Oregon Health & ...

Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy ...

Mr. Kim, 62 years old, a man preparing for retirement, was an office worker diligently attending to his job just a year ago.

A joint research group consisting of Saitama Medical University and Meiji Holdings Co., Ltd. today announced results from a ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) ...

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...

Researchers from The University of Texas MD Anderson Cancer Center will present initial data from six clinical trials during minisymposia at this week’s American Association for Cancer Research (AACR) ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...